A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting
Latest Information Update: 17 Dec 2024
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 12 Dec 2024 Planned End Date changed from 31 Jul 2027 to 15 Mar 2029.
- 12 Dec 2024 Planned primary completion date changed from 31 Jul 2027 to 15 Mar 2029.
- 12 Dec 2024 Planned initiation date changed from 31 Oct 2024 to 29 May 2025.